Nearly half of lymphoma patients treated with Gilead Sciences Inc.’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to presented data.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2019-12-07 14:11:512019-12-07 14:11:51Half of lymphoma patients alive three years after Gilead cell therapy treatment: study
